• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

    22.27 +0.91 (+4.24%)
    Streaming Delayed Price Updated: 10:41 AM EDT, Oct 9, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 276,215
    Open 21.51
    Bid (Size) 22.25 (2)
    Ask (Size) 22.28 (5)
    Prev. Close 21.36
    Today's Range 21.37 - 22.34
    52wk Range 9.900 - 27.20
    Shares Outstanding 9,587,155
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    10 Health Care Stocks With Whale Alerts In Today's Session
    This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
    Via Benzinga

    Performance

    YTD
    +12.7%
    +12.7%
    1 Month
    +12.4%
    +12.4%
    3 Month
    +30.7%
    +30.7%
    6 Month
    +88.8%
    +88.8%
    1 Year
    -4.9%
    -4.9%

    More News

    Read More
    Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts
    Via Benzinga
    Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views
    Via Benzinga
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results
    Via Benzinga
    Viridian (VRDN) Q2 Net Loss Widens 55%
    Via The Motley Fool
    Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    What 5 Analyst Ratings Have To Say About Viridian Therapeutics
    Via Benzinga
    Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
    From Viridian Therapeutics, Inc.
    Via Business Wire
    This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga

    Frequently Asked Questions

    Is Viridian Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Viridian Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Viridian Therapeutics, Inc. - Common Stock trade on?
    Viridian Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Viridian Therapeutics, Inc. - Common Stock?
    The ticker symbol for Viridian Therapeutics, Inc. - Common Stock is VRDN on the Nasdaq Stock Market
    What is the current price of Viridian Therapeutics, Inc. - Common Stock?
    The current price of Viridian Therapeutics, Inc. - Common Stock is 22.27
    When was Viridian Therapeutics, Inc. - Common Stock last traded?
    The last trade of Viridian Therapeutics, Inc. - Common Stock was at 10/09/25 10:41 AM ET
    What is the market capitalization of Viridian Therapeutics, Inc. - Common Stock?
    The market capitalization of Viridian Therapeutics, Inc. - Common Stock is 213.46M
    How many shares of Viridian Therapeutics, Inc. - Common Stock are outstanding?
    Viridian Therapeutics, Inc. - Common Stock has 213M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.